Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective

Expert Rev Clin Pharmacol. 2023 Jan-Jun;16(6):507-517. doi: 10.1080/17512433.2023.2219056. Epub 2023 Jun 5.

Abstract

Introduction: Around 80% of women suffer menopause-related symptoms that affect their daily activities and quality of life. Menopausal hormone therapy (MHT) has proven to be beneficial in relieving these symptoms. Nevertheless, only 20/30% of symptomatic women seek treatment. This has resulted in neglect of a generation of healthcare professionals' (HCPs) education in menopausal medicine and a reduction in the prescription of MHT in menopausal women for over two decades.

Areas covered: The aim of this article was to identify the main barriers that HCPs face for prescribing MHT and menopausal women for using it. Six European experts in menopause agreed on the profiles of women that benefit from MHT and proposed strategies to break down these barriers.

Expert opinion: The most important barrier for HCPs was deficient knowledge of the true evidence-based information, with inadequate training regarding the efficacy and safety of personalized MHT and the real benefit/risk ratio in the treatment of symptomatic women. For patients, fear of developing breast cancer was identified as the single most important barrier. Breaking down barriers is possible, by providing appropriate training and education to HCPs and women. This should result in fully informed, evidence based, shared treatment decisions by women and their physicians.

Keywords: Barriers: fear of breast cancer; hormone therapy use misperceptions; inadequate menopausal education; menopausal hormone therapy; menopausal women.

MeSH terms

  • Estrogen Replacement Therapy* / adverse effects
  • Female
  • Hormone Replacement Therapy / adverse effects
  • Hormones
  • Humans
  • Menopause
  • Quality of Life*

Substances

  • Hormones